Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC4004-0002 in Adults With Asymptomatic Hyperuricemia
NCT06859073Phase 1Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperuricemia comparing NNC4004-0002 with Placebo (2 arms). Primary endpoint: Number of Treatment-emergent adverse events at 28 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
NNC4004-0002
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT06859073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859073.